Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2

Journal of Oral Microbiology

Volumn 2, Issue 2010, 2010, Pages

  Yin, Lei ^a   Swanson, Bryan ^a   An, Jonathan ^a   Hacker, Beth M ^a   Silverman, Gary A ^b   Dale, Beverly A ^a   Chung, Whasun O ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gingival epithelial cells; Host defense; Periopathogen; Protease inhibitor

Indexed keywords

EID: 80855127035     PISSN: None     EISSN: 20002297     Source Type: Journal    
DOI: 10.3402/jom.v2i0.5070     Document Type: Article

References (69)

1. Albandar JM, Rams TE. Global epidemiology of periodontal diseases: an overview. Periodontology 2000 2002; 29: 7-10.
2. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005; 366: 1809-20.
3. Jeffcoat MK, Geurs NC, Reddy MS, Cliver SP, Goldenberg RL, Hauth JC. Periodontal infection and preterm birth: results of a prospective study. J Am Dent Assoc 2001; 132: 875-80.
4. Scannapieco FA, Bush RB, Paju S. Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol 2003; 8: 38-53.
5. Scannapieco FA, Rethman MP. The relationship between periodontal diseases and respiratory diseases. Dent Today 2003; 22: 79-83.
6. Slots J, Ting M. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment. Periodontology 2000 1999; 20: 82-121.
7. Sakamoto M, Takeuchi Y, Umeda M, Ishikawa I, Benno Y. Rapid detection and quantification of five periodontopathic bacteria by real time PCR. Microbiol Immunol 2001; 45: 39-44.
8. Lamont RJ, Jenkinson HF. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev 1998; 62: 1244-63.
9. Holt SC, Kesavalu L, Walker S, Genco CA. Virulence factors of Porphyromonas gingivalis. Periodontology 2000 1999; 20: 168-238.
10. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontology 2000 1994; 5: 78-111.
11. Andrian E, Grenier D, Rouabhia M. Porphyromonas gingivalis- epithelial cell interactions in periodontitis. J Dent Res 2006; 85: 392-403.
12. Saito T, Ishihara K, Kato T, Okuda K. Cloning, expression, and sequencing of a protease gene from Bacteroides forsythus ATCC 43037 in Escherichia coli. Infect Immun 1997; 65: 4888-91.
13. Ishikura H, Arakawa S, Nakajima T, Tsuchida N, Ishikawa I. Cloning of the Tannerella forsythensis (Bacteroides forsythus) siaHI gene and purification of the sialidase enzyme. J Med Microbiol 2003; 52: 1101-7.
14. Murakami Y, Higuchi N, Nakamura H, Yoshimura F, Oppenheim FG. Bacteroides forsythus hemagglutinin is inhibited by N acetylneuraminyllactose. Oral Microbiol Immunol 2002; 17: 125-8.
15. Robertson PB, Lantz M, Marucha PT, Kornman KS, Trummel CL, Holt SC. Collagenolytic activity associated with Bacteroides species and Actinobacillus actinomycetemcomitans. J Periodontal Res 1982; 17: 275-83.
16. Kadowaki T, Yoneda M, Okamoto K, Maeda K, Yamamoto K. Purification and characterization of a novel arginine specific cysteine proteinase (argingipain) involved in the pathogenesis of periodontal disease from the culture supernatant of Porphyromonas gingivalis. J Biol Chem 1994; 269: 21371-8.
17. Chen Z, Potempa J, Polanowski A, Wikstrom M, Travis J. Purification and characterization of a 50 kDa cysteine proteinase (gingipain) from Porphyromonas gingivalis. J Biol Chem 1992; 267: 18896-901.
18. Pike R, McGraw W, Potempa J, Travis J. Lysine and argininespecific proteinases from Porphyromonas gingivalis. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins. J Biol Chem 1994; 269: 406-11.
19. Sugawara S, Nemoto E, Tada H, Miyake K, Imamura T, Takada H. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness. J Immunol 2000; 165: 411-8.
20. Tada H, Sugawara S, Nemoto E, Takahashi N, Imamura T, Potempa J. Proteolysis of CD14 on human gingival fibroblasts by arginine specific cysteine proteinases from Porphyromonas gingivalis leading to down regulation of lipopolysaccharideinduced interleukin 8 production. Infect Immun 2002; 70: 3304-7.
21. Tada H, Sugawara S, Nemoto E, Imamura T, Potempa J, Travis J. Proteolysis of ICAM 1 on human oral epithelial cells by gingipains. J Dent Res 2003; 82: 796-801.
22. Into T, Inomata M, Kanno Y, Matsuyama T, Machigashira M, Izumi Y. Arginine specific gingipains from Porphyromonas gingivalis deprive protective functions of secretory leukocyte protease inhibitor in periodontal tissue. Clin Exp Immunol 2006; 145: 545-54.
23. Magert HJ, Drogemuller K, Raghunath M. Serine proteinase inhibitors in the skin: role in homeostasis and disease. Curr Protein Pept Sci 2005; 6: 241-54.
24. Yin L, Dale BA. Activation of protective responses in oral epithelial cells by Fusobacterium nucleatum and human betadefensin J Med Microbiol 2007; 56: 976-87.
25. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006; 110: 21-35.
26. Cataltepe S, Schick C, Luke CJ, Pak SC, Goldfarb D, Chen P. Development of specific monoclonal antibodies and a sensitive discriminatory immunoassay for the circulating tumor markers SCCA1 and SCCA2. Clin Chim Acta 2000; 295: 107-27.
27. Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin like proteinases cathepsin G and mast cell chymase. J Biol Chem 1997; 272: 1849-55.
28. Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect Immun 2004; 72: 352-8.
29. Chen T, Nakayama K, Belliveau L, Duncan MJ. Porphyromonas gingivalis gingipains and adhesion to epithelial cells. Infect Immun 2001; 69: 3048-56.
30. Lewis JP, Dawson JA, Hannis JC, Muddiman D, Macrina FL. Hemoglobinase activity of the lysine gingipain protease (Kgp) of Porphyromonas gingivalis W83. J Bacteriol 1999; 181: 4905-13.
31. Sharma A, Sojar HT, Glurich I, Honma K, Kuramitsu HK, Genco RJ. Cloning, expression, and sequencing of a cell surface antigen containing a leucine rich repeat motif from Bacteroides forsythus ATCC 43037. Infect Immun 1998; 66: 5703-10.
32. Cronan CA, Potempa J, Travis J, Mayo JA. Inhibition of Porphyromonas gingivalis proteinases (gingipains) by chlorhexidine: synergistic effect of Zn(II). Oral Microbiol Immunol 2006; 21: 212-7.
33. Eley BM, Cox SW. Cathepsin B/L, elastase, tryptase, trypsinand dipeptidyl peptidase IV like activities in gingival crevicular fluid: a comparison of levels before and after periodontal surgery in chronic periodontitis patients. J Periodontol 1992; 63: 412-7.
34. Hernandez Rios M, Sorsa T, Obregon F, Tervahartiala T, Valenzuela MA, Pozo P. Proteolytic roles of matrix metalloproteinase (MMP) 13 during progression of chronic periodontitis: initial evidence for MMP 13/MMP 9 activation cascade. J Clin Periodontol 2009; 36: 1011-7.
35. Curtis MA, Kuramitsu HK, Lantz M, Macrina FL, Nakayama K, Potempa J. Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J Periodontal Res 1999; 34: 464-72.
36. Tipler LS, Embery G. Glycosaminoglycan depolymerizing enzymes produced by anaerobic bacteria isolated from the human mouth. Arch Oral Biol 1985; 30: 391-6.
37. Eley BM, Cox SW. Proteolytic and hydrolytic enzymes from putative periodontal pathogens: characterization, molecular genetics, effects on host defenses and tissues and detection in gingival crevice fluid. Periodontology 2000 2003; 31: 105-24.
38. Potempa Jan RNP. Corruption of innate immunity by bacterial proteases. J Innate Immun 2009; 1: 70-87.
39. Carlisle RNS, Brogdena KA. Degradation of human-and defensins by culture supernatants of Porphyromonas gingivalis strain 381. J Innate Immun 2009; 1: 118-22.
40. Darveau RP, Belton CM, Reife RA, Lamont RJ. Local chemokine paralysis, a novel pathogenic mechanism for Porphyromonas gingivalis. Infect Immun 1998; 66: 1660-5.
41. Tonetti MS, Imboden MA, Lang NP. Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin 8 and ICAM 1. J Periodontol 1998; 69: 1139-47.
42. Moreau T, Baranger K, Dade S, Dallet Choisy S, Guyot N, Zani ML. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008; 90: 284-95.
43. Doumas S, Kolokotronis A, Stefanopoulos P. Anti inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun 2005; 73: 1271-4.
44. Pfundt R, Wingens M, Bergers M, Zweers M, Frenken M, Schalkwijk J. TNF alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase dependent pathway. Arch Dermatol Res 2000; 292: 180-7.
45. Meyer Hoffert U, Wichmann N, Schwichtenberg L, White PC, Wiedow O. Supernatants of Pseudomonas aeruginosa induce the Pseudomonas specific antibiotic elafin in human keratinocytes. Exp Dermatol 2003; 12: 418-25.
46. van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J. Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2000; 278: L51-8.
47. Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 2003; 71: 3766-74.
48. McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR. Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect Immun 2005; 73: 3609-17.
49. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol 2005; 79: 6432-40.
50. Ma G, Greenwell Wild T, Lei K, Jin W, Swisher J, Hardegen N. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV 1 infection. J Exp Med 2004; 200: 1337-46.
51. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF kappa B dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004; 172: 4535-44.
52. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E. Secretory leucoprotease inhibitor binds to NF kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202: 1659-68.
53. Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277: 33648-53.
54. Mulligan MS, Lentsch AB, Huber Lang M, Guo RF, Sarma V, Wright CD. Anti inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol 2000; 156: 1033-9.
55. Cataltepe S, Gornstein ER, Schick C, Kamachi Y, Chatson K, Fries J. Co expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas. J Histochem Cytochem 2000; 48: 113-22.
56. Hamada K, Hanakawa Y, Hashimoto K, Iwamoto M, Kihana T, Hirose S. Gene expression of human squamous cell carcinoma antigens 1 and 2 in human cell lines. Oncol Rep 2001; 8: 347-54.
57. Sakata Y, Arima K, Takai T, SakuraiW, Masumoto K, Yuyama N. The squamous cell carcinoma antigen 2 inhibits the cysteine proteinase activity of a major mite allergen, Der p 1. J Biol Chem 2004; 279: 5081-7.
58. Izuhara K, Kanaji S, Arima K, Ohta S, Shiraishi H. Involvement of cysteine protease inhibitors in the defense mechanism against parasites. Med Chem 2008; 4: 322-7.
59. Kubota T, Itagaki M, Hoshino C, Nagata M, Morozumi T, Kobayashi T. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis affected gingival tissue. J Periodontol 2008; 79: 166-73.
60. Li J, Schwimmbeck PL, Tschope C, Leschka S, Husmann L, Rutschow S. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002; 56: 235-47.
61. Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006; 533: 133-44.
62. Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL. Elafin, an elastase specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008; 283: 32377-85.
63. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1) antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999; 160: 1968-75.
64. Ogawa AT, Brasil de Souza Tde A, de Uzeda M, Jankevicius JV, Jankevicius SI. Characterization of proteolytic activities of Fusobacterium nucleatum. J Endod 2006; 32: 521-3.
65. Darenfed H, Grenier D, Mayrand D. Acquisition of plasmin activity by Fusobacterium nucleatum subsp. nucleatum and potential contribution to tissue destruction during periodontitis. Infect Immun 1999; 67: 6439-44.
66. Arakawa S, Nakajima T, Ishikura H, Ichinose S, Ishikawa I, Tsuchida N. Novel apoptosis inducing activity in Bacteroides forsythus: a comparative study with three serotypes of Actinobacillus actinomycetemcomitans. Infect Immun 2000; 68: 4611-5.
67. Kantyka T, Latendorf T, Wiedow O, Bartels J, Glaser R, Dubin G. Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage. Biol Chem 2009; 390: 1313-20.
68. Katagiri C, Nakanishi J, Kadoya K, Hibino T. Serpin squamous cell carcinoma antigen inhibits UV induced apoptosis via suppression of c JUN NH2 terminal kinase. J Cell Biol 2006; 172: 983-90.
69. Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. Elafin prevents lipopolysaccharideinduced AP 1 and NF kappaB activation via an effect on the ubiquitin proteasome pathway. J Biol Chem 2006; 281: 34730-5.